Affordable Access

deepdyve-link
Publisher Website

Optimal management of mantle cell lymphoma in the primary setting.

Authors
  • Tang, Catherine1, 2
  • Kuruvilla, John1, 2
  • 1 Division of Medical Oncology & Hematology, Princess Margaret Hospital , Toronto , Canada. , (Canada)
  • 2 Department of Medicine, University of Toronto , Toronto , Canada. , (Canada)
Type
Published Article
Journal
Expert Review of Hematology
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 01, 2019
Volume
12
Issue
9
Pages
715–721
Identifiers
DOI: 10.1080/17474086.2019.1639501
PMID: 31268728
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Introduction: The management of mantle cell lymphoma (MCL) has significantly improved since the use of intensified induction and autologous stem cell transplant consolidation. Evolving developments in minimal residual disease detection and novel agent therapy are now challenging this frontline treatment paradigm. Areas covered: This review discusses both the established role of induction and transplant consolidation in MCL, followed by evolving concepts in the use of novel agents in the frontline setting, and the use of minimal residual disease as a driver of MCL management. Expert opinion: In an era of novel agents and improved biologic understanding of MCL, our goal for frontline management should evolve toward personalized therapy for individual patients to maximize efficacy and survival whilst minimizing treatment-related toxicities.

Report this publication

Statistics

Seen <100 times